APA (7th ed.) Citation

John, L., Sauer, S., Hegenbart, U., Dreger, P., Hundemer, M., Müller-Tidow, C., . . . Schönland, S. (2023). Idecabtagene vicleucel is well tolerated and effective in relapsed/refractory myeloma patients with prior allogeneic stem cell transplantation. Transplantation and cellular therapy, 29(10), . https://doi.org/10.1016/j.jtct.2023.06.010

Chicago Style (17th ed.) Citation

John, Lukas, et al. "Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation." Transplantation and Cellular Therapy 29, no. 10 (2023). https://doi.org/10.1016/j.jtct.2023.06.010.

MLA (9th ed.) Citation

John, Lukas, et al. "Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation." Transplantation and Cellular Therapy, vol. 29, no. 10, 2023, https://doi.org/10.1016/j.jtct.2023.06.010.